Skip to content
value.today

GeneWeave Biosciences, Inc.

🇺🇸 San Jose, California, USABiotechnologyFounded 2010
Total raised
$24 M
2 rounds on record
Latest round
$12 M
May 2014
First round on record
Feb 2012
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of GeneWeave Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2014$12 MNo. 2$10 to $50 million

GeneWeave Biosciences, Inc.: Raise no. 2, May 2014

Investors in this round

5 investors had bought by the notice of Jan 15, 2015: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: "Offering of Series B Preferred Stock (""Series B""), warrant to purchase Series B (""Warrant""), the underlying shares of Series B issuable upon exercise of Warrant and the underlying shares of Commo
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Diego Rey · Executive Officer
  • Jason Springs · Executive Officer, Director
  • Nora Bianchi · Executive Officer
  • Steven Tablak · Executive Officer, Director
  • Werner Frei · Executive Officer
  • Kenneth Bahk, Ph.D. · Director
  • Min Cui, Ph.D. · Director
  • Ted Driscoll, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nora Bianchi, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 15, 2015. Read the notice at the SEC.

equity, optionsSEC
Feb 2012$12 MNo. 1$10 to $50 million

GeneWeave Biosciences, Inc.: Raise no. 1, Feb 2012

Investors in this round

3 investors had bought by the notice of Mar 1, 2012: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jason Springs · Executive Officer, Director
  • Steven Tablak · Executive Officer, Director
  • Ted Driscoll · Director
  • Xiangmin Cui · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven Tablak, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 1, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • GeneWeave Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2015).

    SEC Form D · Jan 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2015

That is all the official record says: GeneWeave Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of GeneWeave Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 5 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by GeneWeave Biosciences, Inc.
NameRoleNamed in
Diego ReyExecutive officerJan 2015
Jason SpringsExecutive officerJan 2015
Nora BianchiExecutive officerJan 2015
Steven TablakExecutive officerJan 2015
Werner FreiExecutive officerJan 2015
Jason SpringsDirectorJan 2015
Kenneth Bahk, Ph.D.DirectorJan 2015
Min Cui, Ph.D.DirectorJan 2015
Steven TablakDirectorJan 2015
Ted Driscoll, Ph.D.DirectorJan 2015
Ted DriscollDirectorMar 2012
Xiangmin CuiDirectorMar 2012